Logo

uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington's Disease

Share this
uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington's Disease

uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington's Disease

Shots:

  • The company has completed the enrollment in the first cohort of P- I/II trial involves assessing AMT-130 in 10 patients- out of which six patients received treatment with AMT-130 and four patients received imitation surgery for early manifest HD
  • The company plans to initiate a second clinical study of AMT-130 in the EU in H2’21 while the enrollment of the second dose cohort is expected to initiate in Q3’21
  • The company also plans to initiate an open-label trial of AMT-130 in the EU later this year. The study will enroll 15 patients with early manifest HD across two dose cohorts

  Ref: PRNewswire | Image: Stat News

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions